Clinical trial
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565 is registered in ClinicalTrials.gov with argenx as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Lead sponsor
- argenx
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 4, 2024
- Completion date
- June 30, 2034
- Enrollment
- 680 (estimated)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.